Dlaczego nie należy przerywać terapii IBS w czasie pandemii COVID-19? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2020
Słowa kluczowe:
zespół jelita nadwrażliwego, spazmolityki, trimebutyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zespół jelita nadwrażliwego to schorzenie przewlekłe, które cechuje się częstymi nawrotami objawów wyzwalanymi przez różne czynniki środowiskowe, w tym przewlekły stres. Uzyskanie sukcesu terapeutycznego wymaga wypracowania dobrej relacji lekarz–pacjent, a także zastosowania różnych form leczenia skojarzonego uwzględniającego przywrócenie stanu eubiozy jelitowej, poprawę motoryki przewodu pokarmowego, korektę zaburzeń rytmu wypróżnień oraz ustąpienie dolegliwości bólowych. Osiągnięcie tych celów jest możliwe dzięki zastosowaniu różnych form farmakoterapii o zróżnicowanych mechanizmach działania.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gąsiorowska, A. (2020). Dlaczego nie należy przerywać terapii IBS w czasie pandemii COVID-19? . Medycyna Faktów , 13(2(47), 213-218. https://doi.org/10.24292/01.MF.0220.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34.
2. Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009; 43(6): 541-50.
3. Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology. 2016; 150(6): 1393-407.
4. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016; 150(6): 1257-61.
5. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011; 46: 421-31.
6. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987; 92(6): 1885-93.
7. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006; 101(6): 1288-94.
8. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Review. 2018; 13(4): 1-30.
9. Patel P, Bercik P, Morgan DG et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015; 50: 816-23.
10. Sultan S, Altayar O, Siddique SM et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 [published online ahead of print, 2020 May 11]. Gastroenterology. 2020; S0016-5085(20)30593-X. http://doi.org/10.1053/j.gastro. 2020.05.001.
11. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-4.
12. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106(5): 915-22.
13. Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017; 66(5): 966-74.
14. Chapman RW, Stanghellini V, Geraint M et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013; 108(9): 1508-15.
15. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109(suppl 1): S2-S26.
16. Annahazi A, Roka R, Rosztoczy A et al. Role of antispasmodics in the treatment if irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43.
17. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997; 25(5): 225-46.
18. Roman FJ, Lanet S, Hamon J et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther. 1999; 289(3): 1391-7.
19. Salvioli B. Trimebutibe: A state-of-the-art review. Minerva Gastroenterol Dietol. 2019; 65(3): 229-38.
20. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61.
21. Ruepert L, Quartero AO, de Wit NJ et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011; (8): CD003460. http://doi.org 10.1002/14651858.CD003460.pub3.
22. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7): 712-21.
23. de Bortoli A, Tolone T, Frazzoni M et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018; 31(6): 639-48.
24. Kountouras J, Chatzopoulos D, Zavos C et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002; 49(43): 193‐7.
25. Hawthorn M, Ferrante J, Luchowski E et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988; 2(2): 101-18.
26. Walstab J, Wohlfarth C, Hovius R et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogas-troenterol Motil. 2014; 26(6): 810-20.
27. Liu JH, Chen GH, Yeh HZ et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997; 32(6): 765-8.
28. Enck P. Therapy options in irritable bowel syndrome. A meta-analysis of 121 treatment trials for IBS found PO to be more effective than anti-spasmodics, tricyclic antidepressants, and fiber. Eur J Gastroenterol Hepatol. 2010; 22(12): 1402-11.
29. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014; 48(6): 505-12.
30. Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016; 61(2): 560-71.
31. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364: 22-32.
32. Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol. 2018; 15(10): 589-605.
33. Banasiewicz T, Borycka-Kiciak A, Dobrowolska-Zachwieja A et al. Kliniczne aspekty zastosowania kwasu masłowego w postępowaniu dietetycznym w chorobach jelit. Prz Gastroenterolog. 2010; 5(6): 329-34.
34. Roediger WE. Bacterial short-chain fatty acids and mucosal diseases of the colon. Br J Surg. 1988; 75(4): 346-8.
35. Guilloteau P, Martin L, Eeckhaut V et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2010; 23: 366-84.
36. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2012; 15(2): 204-9.
37. Tarnowski W, Borycka-Kiciak K, Kiciak A et al. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt. 2011; 1: 43-8.
38. Scarpellini E, Lauritano EC, Lupascu A. Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. Dig Liver Dis Supplements. 2007; 1(1): 19-22.
2. Drossman DA, Morris CB, Schneck S et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009; 43(6): 541-50.
3. Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology. 2016; 150(6): 1393-407.
4. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016; 150(6): 1257-61.
5. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011; 46: 421-31.
6. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987; 92(6): 1885-93.
7. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006; 101(6): 1288-94.
8. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Review. 2018; 13(4): 1-30.
9. Patel P, Bercik P, Morgan DG et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol. 2015; 50: 816-23.
10. Sultan S, Altayar O, Siddique SM et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 [published online ahead of print, 2020 May 11]. Gastroenterology. 2020; S0016-5085(20)30593-X. http://doi.org/10.1053/j.gastro. 2020.05.001.
11. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997; 32(9): 920-4.
12. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011; 106(5): 915-22.
13. Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017; 66(5): 966-74.
14. Chapman RW, Stanghellini V, Geraint M et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013; 108(9): 1508-15.
15. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014; 109(suppl 1): S2-S26.
16. Annahazi A, Roka R, Rosztoczy A et al. Role of antispasmodics in the treatment if irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43.
17. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997; 25(5): 225-46.
18. Roman FJ, Lanet S, Hamon J et al. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther. 1999; 289(3): 1391-7.
19. Salvioli B. Trimebutibe: A state-of-the-art review. Minerva Gastroenterol Dietol. 2019; 65(3): 229-38.
20. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61.
21. Ruepert L, Quartero AO, de Wit NJ et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011; (8): CD003460. http://doi.org 10.1002/14651858.CD003460.pub3.
22. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7): 712-21.
23. de Bortoli A, Tolone T, Frazzoni M et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol. 2018; 31(6): 639-48.
24. Kountouras J, Chatzopoulos D, Zavos C et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology. 2002; 49(43): 193‐7.
25. Hawthorn M, Ferrante J, Luchowski E et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988; 2(2): 101-18.
26. Walstab J, Wohlfarth C, Hovius R et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogas-troenterol Motil. 2014; 26(6): 810-20.
27. Liu JH, Chen GH, Yeh HZ et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997; 32(6): 765-8.
28. Enck P. Therapy options in irritable bowel syndrome. A meta-analysis of 121 treatment trials for IBS found PO to be more effective than anti-spasmodics, tricyclic antidepressants, and fiber. Eur J Gastroenterol Hepatol. 2010; 22(12): 1402-11.
29. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014; 48(6): 505-12.
30. Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016; 61(2): 560-71.
31. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364: 22-32.
32. Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol. 2018; 15(10): 589-605.
33. Banasiewicz T, Borycka-Kiciak A, Dobrowolska-Zachwieja A et al. Kliniczne aspekty zastosowania kwasu masłowego w postępowaniu dietetycznym w chorobach jelit. Prz Gastroenterolog. 2010; 5(6): 329-34.
34. Roediger WE. Bacterial short-chain fatty acids and mucosal diseases of the colon. Br J Surg. 1988; 75(4): 346-8.
35. Guilloteau P, Martin L, Eeckhaut V et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev. 2010; 23: 366-84.
36. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2012; 15(2): 204-9.
37. Tarnowski W, Borycka-Kiciak K, Kiciak A et al. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt. 2011; 1: 43-8.
38. Scarpellini E, Lauritano EC, Lupascu A. Efficacy of butyrate in the treatment of diarrhoea-predominant irritable bowel syndrome. Dig Liver Dis Supplements. 2007; 1(1): 19-22.